Buscar
01/01/2022
CES1 and SLC6A2 Genetic Variants As Predictors of Response To Methylphenidate in Autism Spectrum Disorders
Hernandez, MH, Bote, V, Serra-LLovich, A, Cendros, M, Salazar, J, Mestres, C, Guijarro, S, Alvarez, A, Lamborena, C, Mendez, I, Sanchez, B, Hervas, A, Arranz, MJ. CES1 and SLC6A2 Genetic Variants As Predictors of Response To Methylphenidate in Autism Spectrum Disorders. Pharmacogenomics & Personalized Medicine. 2022; 15DOI:10.2147/PGPM.S377210. PMID:36393977. IF:1.900(Q4/9D).
01/01/2022
Association between control group therapy and magnitude of clinical benefit of cancer drugs
Molto C., Tibau A., Bujosa A., Tapia J.C., Mittal A., Tamimi F., Amir E.. Association between control group therapy and magnitude of clinical benefit of cancer drugs. Scientific Reports. 2022; 12(1)DOI:10.1038/s41598-022-25983-9. PMID:36494465. IF:(Q/D).
01/01/2022
A Paradigm Shift for Resectable Non-Small Cell Lung Cancer
Isla D., Majem M.. A Paradigm Shift for Resectable Non-Small Cell Lung Cancer. ARCHIVOS DE BRONCONEUMOLOGIA. 2022; 58(12)DOI:10.1016/j.arbres.2022.04.004. PMID:35595655. IF:8.000(Q1/2D).
01/01/2022
A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial)
Argilés G., Valladares-Ayerbes M., Viéitez J.M., García-Paredes B., Rodríguez-Garrote M., Rivera F., Goldberg R.M., Ciardiello F., Tabernero J.M., Goldberg R., Argilés, Tabernero J., Mulet N., Limón M.L., Valladares M., Jiménez P., Vieitez J.M., Grávalos C., García-Alfonso P., Santos C., Páez D., Tobeña M., Sastre J., García Paredes B., Benavides M., Aranda E., Cano M.T., Loupakis F., Rguez Garrote M., Guillén C., Rivera M.F., Safont J., Hiret S., Bennouna J., Pannier D., Malka D., Falcone A., Cremolini C., The. A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial). EUROPEAN JOURNAL OF CANCER. 2022; 177DOI:10.1016/j.ejca.2022.09.037. PMID:36335783. IF:8.400(Q1/2D).